valpromide
Valpromide is a carboxamide derivative of valproic acid used in the treatment of epilepsy and some affective disorders. It is rapidly metabolised (80%) to valproic acid but has anticonvulsant properties itself. It may produce more stable plasma levels than valproic acid or sodium valproate and may be more effective at preventing febrile seizures. However, it is over one hundred times more potent as an inhibitor of liver microsomal epoxide hydrolase. This makes it incompatible with carbamazepine and can affect the ability of the body to remove other toxins. Valpromide is no safer during pregnancy than valproic acid. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Earliest trial started May 1, 2013 (NCT02556320)
Timeline
No events for the selected filters.
Chemistry & pharmacology
SMILES
CCCC(CCC)C(N)=O- Mol. weight
- 143.23 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaValpromide ↗
- ChEMBLCHEMBL93836 ↗
Also known as
- 2-ethylvaleramide
- 2-propylpentamide
- depamide
- dipropylacetamide
- dipropylacetamide
- valproic acid amide
- valpromide
- valpromide
- valpromide
- valpromide
- valpromide
- valpromide
- valpromide
- valpromide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02556320 | N/A | May 1, 2013 | Rouen Normandy University |
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Rouen Normandy University | Academic/Hospital | 1 | 1 | 1 | 2013 |